The Food and Drug Administration in the US has just approved Cobenfy, which one researcher referred to as a "game changer" ...

A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol Myers Squibb, agreeing with counsel for the ...

From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...

Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.

Warren Buffett is famous for being a value investor while Peter Lynch tended to be growth-oriented. Some investors are ...

Patients with a fast-spreading blood cancer respond well to outpatient treatment with CAR-T therapy, a new study found.

For the second time in 19 months, a federal judge in New York has dismissed a lawsuit claiming that Bristol Myers Squibb slow ...

District Judge Jesse Furman ruled that the plaintiff, UMB Bank, does not have standing to bring the case against Bristol ...

A health communications partnership has been launched today by UK strategic comms agency Lexington Communications and US ...

Patients who received subcutaneous daratumumab plus bortezomib, lenalidomide, and dexamethasone (VRd) had better outcomes ...

One of the first no-brainer dividend stocks to buy with $100 right now is AT&T. At recent prices, America's second-largest telecommunications business by revenue offers a juicy 5.1% dividend yield.

As part of this shift in focus, Schwarzer stepped down as CEO, with Mary Beth Harler appointed as his replacement. Harler joined IGM in 2021 as president of autoimmunity and inflammation following an ...